The Remember Me feature is an automatic login process which creates a cookie on the hard drive of your computer containing a unique identifier which ASCO.org will utilize to remember you by, thereby avoiding the need to enter username and password upon subsequent visits to ASCO.org. DO NOT select this option if you share this computer with others since transactional, personal, or member only information will be accessible by other users.

To activate the Remember Me option, click the empty check box when signing in to the site. The Remember Me functionality is deactivated at the logout.

For additional information please review our Privacy Policy.

Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.

Print

Sub-category:
Cancer-Related Complications

Category:
Patient Care

Meeting:
2009 ASCO Annual Meeting

Abstract No:
9511

Citation:
J Clin Oncol 27:15s, 2009 (suppl; abstr 9511)

Author(s):
J. L. Ryan, C. Heckler, S. R. Dakhil, J. Kirshner, P. J. Flynn, J. T. Hickok, G. R. Morrow; University of Rochester Medical Center, Rochester, NY; Wichita CCOP, Witchita, KS; HOACNY CCOP, Syracuse, NY; Metro-MN CCOP, St. Louis Park, MN

Abstract:

Background: Despite the widespread use of antiemetics, post-chemotherapy nausea and vomiting continue to be reported by up to 70% of patients receiving chemotherapy. Ginger (Zingiber Officinale), an ancient spice, is used by practitioners worldwide to treat nausea and vomiting. We conducted a multi-site, phase II/III randomized, placebo-controlled, double-blind clinical trial to assess the efficacy of ginger for chemotherapy-related nausea in cancer patients at the University of Rochester-affiliated Community Clinical Oncology Program (CCOP) member sites. Methods: Cancer patients who experienced nausea following any chemotherapy cycle and were scheduled to receive at least three additional cycles were eligible. Patients were randomized into four arms: 1) placebo, 2) 0.5g ginger, 3) 1.0g ginger, or 4) 1.5g ginger. All patients received 5-HT3 receptor antagonist antiemetics on Day 1 of all cycles and took three 250mg capsules of ginger or placebo twice daily for six days starting three days before the first day of the next two cycles. Patients reported the severity of nausea during the morning, afternoon, evening, and night on a 7-point semantic rating scale ('1' = 'Not at all Nauseated' and '7' = "Extremely Nauseated") for Days 1-4 of each cycle. The goal was to determine if ginger was more effective than placebo in controlling chemotherapy-related nausea in participants given a 5-HT3 receptor antagonist antiemetic. Results: A total of 644 patients were accrued (90% female, mean age = 53). Breast (66%), alimentary (6.5%), and lung (6.1%) cancers were the most common cancer types. Analysis of covariance (ANCOVA) examined change in nausea in the four study arms on Day 1 of cycles 2 and 3. All doses of ginger significantly reduced nausea (p=0.003). The largest reduction in nausea occurred with 0.5g and 1.0g of ginger. Also, time of day had a significant effect on nausea (p<0.001) with a linear decrease over 24 hours for patients using ginger. Conclusions: Ginger supplementation at daily dose of 0.5g-1.0g significantly aids in reduction of nausea during the first day of chemotherapy. Supported by NCI PHS grants 1R25CA10618 and U10CA37420.


Abstract Disclosures

Faculty and Discussant Disclosures

Annual Meeting Planning Committee Disclosures

2009 Annual Meeting Proceedings Part I Errata

Abstracts that were granted an exception in accordance with ASCO's Conflict of Interest Policy and are designated with a caret symbol (^) here and in the print version.


  Associated Presentation(s):

    

1. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.

Meeting: 2009 ASCO Annual Meeting
Presenter: Julie L Ryan, PhD, MPH
Session: Patient and Survivor Care (Oral Presentation)


  Other Abstracts in this Sub-Category:

    

1. State laws and regulations covering fertility preservation for cancer patients.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 9509   First Author: S. T. Vadaparampil
Category: Patient Care - Cancer-Related Complications

    

2. Neuroprotective effect of SSRI among 781 cancer patients receiving chemotherapy: A URCC CCOP Study.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 9512   First Author: P. Jean-Pierre
Category: Patient Care - Cancer-Related Complications

    

3. Use of age and BMD to predict fracture risk in men on androgen deprivation therapy.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 9517   First Author: D. Lin
Category: Patient Care - Cancer-Related Complications

    

More...


  Abstracts by J. L. Ryan:

    

1. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.

Meeting: 2009 ASCO Annual Meeting   Abstract No: 9511   First Author: J. L. Ryan
Category: Patient Care - Cancer-Related Complications

    

2. Two studies from the JP Wilmot Cancer Center on the relationship of treatment, expectations, and race with post-treatment skin reactions reported by cancer patients.

Meeting: 2006 ASCO Annual Meeting   Abstract No: 18560   First Author: J. L. Ryan
Category: Patient and Survivor Care - Quality-of-Life Management

    

More...


  Presentations by J. L. Ryan:

    

1. Ginger for chemotherapy-related nausea in cancer patients: A URCC CCOP randomized, double-blind, placebo-controlled clinical trial of 644 cancer patients.

Meeting: 2009 ASCO Annual Meeting
Presenter: Julie L Ryan, PhD, MPH
Session: Patient and Survivor Care (Oral Presentation)

    

More...


  Educational Book Manuscripts by J. L. Ryan:

    

No items found.




 
2318 Mill Road, Suite 800, Alexandria, VA 22314   |   phone: (571) 483-1300
© 2005-2009 American Society of Clinical Oncology (ASCO).  All rights reserved worldwide.